Companies in #Inflammation

Antares Therapeutics is a clinical-stage small molecule biopharmaceutical company developing oral and injectable therapies for autoimmune and inflammatory diseases. The company is headquartered in Princeton, New Jersey, and was acquired by Novartis in 2026.

Avere Therapeutics is a clinical-stage immunology company developing drugs for autoimmune and inflammatory diseases. The company was formed from the former Akero Therapeutics team and entered the public markets via a reverse merger, also acquiring rights to a Hansoh Pharmaceutical drug for $120M.

Caldera Therapeutics is a privately held biopharmaceutical company developing targeted therapies for immunology and inflammation. In 2026, the company announced plans to go public via a reverse merger transaction raising approximately $478M collectively with Vidya Therapeutics.

South San Francisco biotech pioneering next-generation bispecific antibodies for immunology and inflammation using its DualScreen bispecific discovery engine.

Biotech developing disease-controlling treatments for COPD and other neutrophil-driven inflammatory respiratory diseases. Lead candidate EXPD-101 is an oral, once-daily DPP1 inhibitor advancing into a global Phase 2 COPD trial. Backed by Sanofi.

Family-owned German pharmaceutical company focused on pain management and adjacent therapies; in September 2026 it agreed to acquire Bayer's oncology drug Stivarga for up to 375 million euros.

HCW Biologics is a clinical-stage biopharmaceutical company developing novel immunotherapies for chronic, low-grade inflammation and related diseases. Its pipeline includes HCW9302, an injectable IL-2 fusion protein complex in clinical trials for alopecia areata; HCW11-018b, a tetra-valent T-cell engager; and multifunctional fusion molecules combining cytokines with checkpoint blockade. The company also develops reagents for NK-cell and CAR-therapy production under licensing arrangements with partners such as Wugen and WY Biotech.

Incyte is a oncology / inflammation company. See today's news for the latest developments.

Biotech developing precision immunology and inflammation medicines, with a pipeline piece licensed from Kira Pharmaceuticals targeting the Tavneos (C5aR) space.

Clinical-stage biotech developing oral NLRP3 inflammasome inhibitors, led by dapansutrile (OLT1177), which has advanced from discovery into later-stage clinical development across inflammatory and age-related diseases.

Danish biotech whose nGen platform discovers fully synthetic oral macrocyclic peptides (nCycles) that pair biologic-like target specificity with the convenience of an oral pill.

RayThera is a San Diego-based private biotech developing small-molecule therapeutics in immunology. Founded in 2023 with a $110M Series A, the company is being acquired by Biogen in a deal worth up to $1B, marking a major exit for the immunology-focused startup.

Bioelectronic medicine company whose rechargeable vagus nerve implant delivers electrical doses to treat inflammatory and autoimmune disease, led by rheumatoid arthritis.

Swedish Orphan Biovitrum (Sobi) is a global specialty biopharmaceutical company focused on rare diseases, with a portfolio spanning hematology, immunology, and specialty care. The company markets hemophilia treatments (Eloctate, Alprolix), immunology products (Kineret, Gamifant), and specialty therapeutics, and is expanding its rare-disease pipeline through both internal R&D and acquisitions.

Clinical-stage immunoregulatory therapeutics company built on tissue regulatory T cell biology, combining high-resolution human tissue sequencing, computational biology and translational assay systems in its Deep Biology platform.